|Bid||10.51 x 1800|
|Ask||10.92 x 4000|
|Day's range||10.37 - 11.77|
|52-week range||10.37 - 39.12|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||32.38|
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in four upcoming virtual investor conferences. B. Riley Virtual Oncology Investor Conference Thursday, January 27, 20228:00AM PT/11:00AM ET 4th Annual Guggenheim Oncology DayWednesday, February 9, 20221:00PM PT/4:00PM E
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.
The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.